Lantus in the Treatment of Type 1 Diabetes Children
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
In this study, we plan to examine the difference in effect on blood glucose control in
patients who will be on either conventional insulin therapy (i.e. using NPH and Humalog twice
daily, injected separately) or on intensive insulin management (IIM-several shots of short
acting and Glargine insulin). Those on IIM will be mixing the insulin Glargine with the
short-acting insulin analog prior to injecting. The Hemoglobin A1c (HbA1c) results will be
used to monitor blood glucose control over a 6 month period. Twice during the course of the
study, a continuous glucose monitoring system (CGMS-a device the size of a pager that records
blood sugar readings every 5 minutes) will be used to record all the changes in the blood
glucose levels occurring over a 72-hour period.